NASDAQ:RVLP
READ THE FULL RVLP RESEARCH REPORT
Best Eye Drop for Drooping Lids Award by NewBeauty
RVL Pharmaceuticals, plc’s (NASDAQ:RVLP) Upneeq® was selected as the winner in the professional treatment category as “Best Eye Drop for Drooping Lids” in the NewBeauty 13th Annual Beauty Awards. Upneeq was competing along with more than 10,000 other products for awards and was one of 399 that were selected in a variety of categories. Criteria for the award required the product to solve an aesthetic concern and meet NewBeauty’s testing standards.
Members of the independent panel that selected Upneeq were gathered from an esteemed group of opinion leaders, medical and industry professionals and advisors. One of the physician judges noted that Upneeq works in both ptotic eyes in about five minutes, providing a one to two millimeter lift. The award will be included as a segment in the April 4, 2023 issue of NewBeauty. We expect this award will increase awareness of Upneeq and favorably affect product perception.
Management Interviews with CEO Brian Markison and VP of Sales Aaron Green
RVL’s CEO, Brian Markison and VP of Sales Aaron Green participated in a series of interviews which discussed the company’s commercialization strategy for Upneeq, recent confirmatory research published in the Journal of Plastic, Reconstructive and Aesthetic Surgery, Upneeq’s mechanism of action and trends in the aesthetics industry among other topics. See below for links to the interviews:
➢ UPNEEQ: RVL Pharmaceuticals' Compelling Product
➢ RVL Pharmaceuticals' Aesthetics Strategy
➢ Further Support for RVL Pharmaceuticals' UPNEEQ
➢ RVLP: How Does UPNEEQ Work and What is Ptosis?
➢ RVL Pharmaceuticals' UPNEEQ Riding the Multi-Billion Dollar Wave in Aesthetics
➢ RVL Pharmaceuticals' UPNEEQ: A Complement to the Aesthetics Market
➢ A Conversation with RVL Pharmaceuticals: What's Happening in the Industry?
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
________________________
1. Source: Screenshot from video interview.